Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Seven Years Later: TAVR Didn't Blink 😎🫀

3:28
 
Share
 

Manage episode 517706088 series 2740117
Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

🫀 TAVR or SAVR? The 7-Year Truth

New 7-year results from the PARTNER-3 trial (NEJM) show that in low-risk patients with severe symptomatic aortic stenosis, TAVR holds pace with surgery — delivering comparable survival, stroke rates, rehospitalization, valve durability, and quality-of-life outcomes.

🔎 Highlights

• Composite events: 34.6% (TAVR) vs 37.2% (SAVR)

• Mortality: 19.5% vs 16.8%

• Valve failure: 6.9% vs 7.3%

• Aortic gradients remain low in both groups

💡 Clinical rhythm: less AF with TAVR; more pacemakers and paravalvular leak.

This study reinforces a simple truth: in the right low-risk patient, TAVR is not just less invasive — it's durable.

#Cardiology #StructuralHeart #AorticStenosis #TAVR #SAVR #NEJM

  continue reading

772 episodes

Artwork
iconShare
 
Manage episode 517706088 series 2740117
Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

🫀 TAVR or SAVR? The 7-Year Truth

New 7-year results from the PARTNER-3 trial (NEJM) show that in low-risk patients with severe symptomatic aortic stenosis, TAVR holds pace with surgery — delivering comparable survival, stroke rates, rehospitalization, valve durability, and quality-of-life outcomes.

🔎 Highlights

• Composite events: 34.6% (TAVR) vs 37.2% (SAVR)

• Mortality: 19.5% vs 16.8%

• Valve failure: 6.9% vs 7.3%

• Aortic gradients remain low in both groups

💡 Clinical rhythm: less AF with TAVR; more pacemakers and paravalvular leak.

This study reinforces a simple truth: in the right low-risk patient, TAVR is not just less invasive — it's durable.

#Cardiology #StructuralHeart #AorticStenosis #TAVR #SAVR #NEJM

  continue reading

772 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play